Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01092390 · ClinicalTrials.gov registry record · Phase 3
Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease
A Phase 3 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
NCT01092390: Completed Phase 3 study, sponsored by Johns Hopkins University.
NCT01092390 is a Phase 3 study that has completed, run by Johns Hopkins University. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01092390, a Phase 3 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
Study Summary
In this application the investigators describe plans for a randomized controlled cross-over trial to determine the effects of omega-3 fatty acid supplementation on urine protein excretion in 30 adults with diabetes (NIDDM) and kidney disease defined by the presence of proteinuria.
Interventions
- DIETARY_SUPPLEMENT Lovaza (fish oil)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01092390
The ClinicalTrials.gov registry entry for NCT01092390 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lovaza (fish oil) is the first listed.
NCT01092390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01092390 about?
NCT01092390 is a clinical study titled "Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease". In this application the investigators describe plans for a randomized controlled cross-over trial to determine the effects of omega-3 fatty acid supplementation on urine protein excretion in 30 adults with diabetes (NIDDM) and kidney disease defined by the presence of proteinuria.
What is the current status of trial NCT01092390?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2010-03. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01092390?
The interventions under investigation include: Lovaza (fish oil) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01092390?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.